Mednet Logo
Events
ASTRO 2026 Annual Meeting, Boston. Data to Dialogue: Communicating Radiotherapy’s Value to Advance Care

From plenary to practice.

Boston, Massachusetts

ASTRO has partnered with Mednet to turn select sessions into peer discussions. Create an account to get notified when they go live.

First discussion opens Sunday, September 27.

Sessions covered

  1. CT 01: Clinical Trials Session

    1:30 – 3:00 pm ETGrand Ballroom
    • Kenneth Rosenzweig, MD, FASTRO · Icahn School of Medicine at Mount Sinai
    • Farzan Siddiqui, MD, PhD, MBA, FASTRO · Henry Ford Hospital / Wayne State University

  2. PL 01: Plenary Session

    1:30 – 3:00 pm ETGrand Ballroom
    • Kenneth Rosenzweig, MD, FASTRO · Icahn School of Medicine at Mount Sinai
    • Farzan Siddiqui, MD, PhD, MBA, FASTRO · Henry Ford Hospital / Wayne State University

  3. LBA 01: Late-breaking Abstract Session

    2:15 – 3:30 pm ETRoom 210
    • Beth Beadle, MD, PhD, FASTRO · Stanford University
    • Rachel Jimenez, MD, FASTRO · Massachusetts General Hospital
Adnan M. Elhammali, MD

“I use Mednet to search for answers to clinical questions that I encounter during my routine practice. I often find my questions have been asked previously and have highly valuable answers from experienced disease site experts in radiation oncology. I also receive regular emails from Mednet with the most recent questions which often discuss new research developments. This helps me stay up to date on new studies and survey how others are interpreting and implementing new findings into daily practice.”

Adnan M. Elhammali, MD

Radiation Oncology

Northeast Georgia Health System

WHAT IS MEDNET

Where physicians weigh in

Beyond the meeting, Mednet is where physicians compare how they actually practice. Every answer carries a name and a credential.

Mednet Community

Mednet Member

Radiation Oncology

Are you offering 5-fraction SBRT for intermediate-risk prostate, or staying with moderate hypofractionation?

11 replies7 agreedRadiation Oncology
Invited Expert

Mednet Expert

Radiation Oncology • Beth Israel Deaconess Medical Center

For favorable intermediate-risk disease I now default to 5 fractions with fiducials and a rectal spacer. Toxicity has held up in the randomized data and patients strongly prefer the shorter course. For unfavorable intermediate-risk I still talk through 20 fractions...

1 in 3

That's how often physicians change their patient approach based on something they read on Mednet.